Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s

Toxicology and Applied Pharmacology

Volumn 205, Issue 3, 2005, Pages 237-246

  Di Consiglio, Emma ^a   Meneguz, Annarita ^a   Testai, Emanuela ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cytochrome P450; Human liver; Imipramine; Inhibition; Metabolism; Organophosphorothionate pesticides

Indexed keywords

CYTOCHROME P450; IMIPRAMINE; ORGANOPHOSPHATE PESTICIDE;

ARTICLE; CONTROLLED STUDY; DESULFURIZATION; DRUG ACTIVITY; ENZYME DEGRADATION; EVALUATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER MICROSOME;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; HUMANS; IMIPRAMINE; LIVER; MICROSOMES, LIVER; ORGANOTHIOPHOSPHORUS COMPOUNDS; OXIDOREDUCTASES, N-DEMETHYLATING; PESTICIDES;

EID: 19444374624     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2004.10.009     Document Type: Article

References (41)

1. S.E. Ball, D. Ahern, J. Scatina, and J. Kao Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs and effects on human epatic CYP3A4, CYP2C9, and CYP1A2 Br. J. Clin. Pharmacol. 43 1997 619 626
2. J. Barre Drug registration file prerequisites for European procedures Ann. Pharm. Fr. 62 2004 207 213
3. K. Brosen Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2 Clin. Pharmacokinet. 29 1995 20 25
4. K. Brosen Some aspects of genetic polymorphism in the biotransformation of antidepressants Therapie 59 2004 5 12
5. K. Brosen, S.V. Otton, and L.F. Gram Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype Clin. Pharmacol. Ther. 40 1986 543 549
6. K. Brosen, T. Zeugin, and U.A. Meyer Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine Clin. Pharmacol. Ther. 49 1991 609 617
7. K. Brosen, E. Skjelbo, and K.K. Nielsen Imipramine: a model drug for P450 research Methods Enzymol. 272 1996 177 187
8. F.M. Buratti, M.T. Volpe, L. Fabrizi, A. Meneguz, L. Vittozzi, and E. Testai Kinetic parameters of OPT pesticide desulfuration by c-DNA expressed human CYPs Environ. Toxicol. Pharmacol. 11 2002 181 190
9. F.M. Buratti, M.T. Volpe, A. Meneguz, L. Vittozzi, and E. Testai CYP-specific bioactivation of four organophosphorothionate pesticides by human liver microsomes Toxicol. Appl. Pharmacol. 186 2003 143 154
10. A.M. Butler, and M. Murray Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation J. Pharmacol. Exp. Ther. 280 1997 966 973
11. G. Carrier, and R.C. Brunet A toxicokinetic model to assess the risk of azinphosmethyl exposure in humans through measures of urinary elimination of alkylphosphates Toxicol. Sci. 47 1999 23 32
12. W.A. Daniel, M. Syrek, Z. Ryoko, and J. Wojcikowski Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes Pol. J. Pharmacol. 53 2001 351 357
13. J.A. Halpert, D. Hammond, and R.A. Neal Inactivation of purified rat liver cytochrome P-450 during the metabolism of parathion (Diethyl-p- nitrophenyl-phosphorothionate) J. Biol. Chem. 255 1980 1080 1089
14. L.D. Heimark, L. Wienkers, K. Kunze, M. Gibaldi, C. Eddy, W.F. Trager, R.A. O'Reilly, and D.A. Goulart The mechanism of the interaction between amiodarone and warfarin in humans Clin. Pharmacol. Ther. 51 1992 398 407
15. S.M. Huang, and L.J. Lesko Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J. Clin. Pharmacol. 44 2004 559 569
16. J.M. Hunsballe, and J.C. Djurhuus Clinical options of imipramine in the management of urinary incontinence Urol. Res. 29 2001 118 125
17. P.K. Keel, J.E. Mitchell, T.L. Davis, and S.J. Crow Long-term impact of treatment in women diagnosed with bulimia nervosa Int. J. Eat. Disord. 31 2002 151 158
18. E. Koyama, D.R. Sohn, G. Shin, K. Chiba, J.G. Shin, Y.H. Kim, H. Echizen, and T. Ishizaki Metabolic disposition of imipramine in oriental subjects: relation to metoprolol a-hydroxylation and S-mephenytoin 4′-hydroxilation phenotypes J. Pharmacol. Exp. Ther. 271 1994 860 867
19. E. Koyama, K. Chiba, M. Tani, and T. Ishizaki Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs J. Pharmacol. Exp. Ther. 281 1997 1199 1210
20. C. Kuplich-Barcellos, M.R. Chitolina-Schetinger, R. Dutra-Dias, and J.J. Freitas-Sarkis In vitro effect of central nervous system active drugs on the ATPase-ADPase activity and acetylcholinesterase activity from cerebral cortex of adult rats Gen. Pharmacol. 31 1998 563 567
21. A. Lemoine, J.C. Gautier, D. Azoulay, K. Kiffel, C. Belloc, F.P. Guengerich, P. Maurel, P. Beaunne, and J.P. Leroux Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver Mol. Pharmacol. 43 1993 827 832
22. H. Madsen, B.B. Rasmussen, and K. Brosen Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4 Clin. Pharmacol. Ther. 61 1997 319 324
23. T.C. Muller, J.B.T. Rocha, V.M. Morsch, R.T. Neis, and M.R. Chitolina-Schetinger Antidepressant inhibit human acetylcholinesterase and butyrylcholinesterase activity Biochim. Biophys. Acta 1586 2002 92 98
24. R.J. Nolan, D.L. Rick, N.L. Freshour, and J.H. Saunders Chlorpyrifos: pharmacokinetics in human volunteers Toxicol. Appl. Pharmacol. 73 1984 8 15
25. B.J. Norman, R.F. Poore, and R.A. Neal Studies of the binding of sulfur released in the mixed-function oxidase-catalyzed metabolism of diethyl p-nitrophenyl phosphorothioate (parathion) to diethyl p-nitrophenyl phosphate (paraoxon) Biochem. Pharmacol. 23 1974 1733 1744
26. H.J. Olguin, H.J. Cook, J.F. Perez, and A.I. Lares Clinical evidence of an interaction between imipramine and acetylsalicylic acid on protein binding in depressed patients Clin. Neuropharmacol. 25 2002 32 36
27. M.L. Rigas, M.S. Okino, and J.J. Quackenboss Use of pharmacokinetic model to assess chlorpyrifos exposure and dose in children, based on urinary biomarker measurement Toxicol. Sci. 61 2001 374 381
28. F.R. Sallee, and B.G. Pollock Clinical pharmacokinetics of imipramine and desipramine Clin. Pharmacokinet. 18 1990 346 364
29. B.A. Schurdut, L. Barraj, and M. Francis Aggregate exposures under the food quality protection act: an approach using chlorpyrifos Reg. Toxicol. Pharmacol. 28 1998 165 177
30. E. Skjelbo, K. Brosen, J. Hallas, and L.F. Gram The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine Clin. Pharmacol. Ther. 49 1991 18 23
31. L.G. Sultatos Mammalian toxicology of organophosphorus pesticides J. Toxicol. Environ. Health 43 1994 271 289
32. J. Tang, Y. Cao, R.L. Rose, A.A. Brimfield, D. Dai, J.A. Goldstein, and E. Hodgson Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes Drug Metab. Dispos. 29 2001 1201 1204
33. J. Tang, Y. Cao, R.L. Rose, and E. Hodgson In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos Chem.-Biol. Interact. 141 2002 229 241
34. US Food and Drug Administration Guidance for industry-drug metabolism/drug interaction studies in the drug development process: studies in vitro 1997 FDA Washington, DC
35. K.A. Usmani, R.L. Rose, and E. Hodgson Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals Drug Metab. Dispos. 31 2003 384 391
36. A.C. Volkers, J.H.M. Tulen, W. Van den Broek, J.A. Bruijn, J. Passchier, and L. Pepplinkhuizen 24-hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder Eur. Neuropsychopharmacol. 12 2002 273 278
37. L.L. Von Moltke, D.J. Greenblatt, S.X. Duan, J.P. Daily, J.S. Harmatz, and R.I. Shader Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo J. Pharm. Sci. 87 1998 1184 1189
38. L.L. Von Moltke, D.J. Greenblatt, J. Schmider, C.E. Wright, J.S. Harmatz, and R.I. Shader In vitro approaches to predicting drug interactions in vivo Biochem. Pharmacol. 55 1998 113 122
39. J. Wojcikowski, and W.A. Daniel Distribution interactions between perazine and antidepressant drugs. In vivo studies Pol. J. Pharmacol. 52 2000 449 457
40. T.J. Yang, K.W. Krausz, J. Sai, F.J. Gonzalez, and H.V. Gelboin Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism Drug Metab. Dispos. 27 1999 102 109
41. N.R. Zinner, S.C. Koke, and L. Viktrup Pharmacotherapy for stress urinary incontinence: present and future options Drugs 64 2004 1503 1516